Osaka, Japan

Takahiro Nekado

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takahiro Nekado: Innovator in Pharmaceutical Chemistry

Introduction

Takahiro Nekado is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of therapeutic agents. With a total of 3 patents, his work focuses on innovative compounds that address various medical conditions.

Latest Patents

One of his latest patents is the ethane-sulfonate salt of a quinoline derivative. This invention relates to a compound that exhibits Axl-inhibiting activity, making it useful as a prophylactic and therapeutic agent for immune diseases and cancer. Another notable patent involves an amine salt and its crystals, which serve as a therapeutic agent for underactive bladder. This compound is designed to have a low risk of side effects and can be administered orally, enhancing its practicality as a medication.

Career Highlights

Takahiro Nekado has worked with notable companies in the pharmaceutical industry, including Ono Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Takahiro has collaborated with esteemed colleagues such as Shizuka Ono and Hideomi Kijima. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Takahiro Nekado's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a key inventor in the field. His work continues to pave the way for new therapeutic solutions that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…